A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)

• Published in: Journal of the American Society of Nephrology Vol. 31; no. 11; pp. 2653 - 2666
• Main Authors: Toussaint, Nigel D., Pedagogos, Eugenia, Lioufas, Nicole M., Elder, Grahame J., Pascoe, Elaine M., Badve, Sunil V., Valks, Andrea, Block, Geoffrey A., Boudville, Neil, Cameron, James D., Campbell, Katrina L., Chen, Sylvia S.M., Faull, Randall J., Holt, Stephen G., Jackson, Dana, Jardine, Meg J., Johnson, David W., Kerr, Peter G., Lau, Kenneth K., Hooi, Lai-Seong, Narayan, Om, Perkovic, Vlado, Polkinghorne, Kevan R., Pollock, Carol A., Reidlinger, Donna, Robison, Laura, Smith, Edward R., Walker, Robert J., Wang, Angela Yee Moon, Hawley, Carmel M.
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.11.2020
• Subjects: Aged; Aorta, Abdominal; Clinical Research; Double-Blind Method; Female; Fibroblast Growth Factors - blood; Glomerular Filtration Rate; Humans; Hyperphosphatemia - blood; Hyperphosphatemia - drug therapy; Hyperphosphatemia - etiology; Lanthanum - adverse effects; Lanthanum - therapeutic use; Male; Middle Aged; Parathyroid Hormone - blood; Phosphates - blood; Phosphates - urine; Pulse Wave Analysis; Renal Insufficiency, Chronic - blood; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - physiopathology; Tomography, X-Ray Computed; Vascular Calcification - diagnostic imaging; lanthanum carbonate; phosphate; cardiovascular disease; phosphate binders; arterial compliance; vascular calcification

Hyperphosphatemia is associated with increased fibroblast growth factor 23 (FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering medication on vascular calcification and arterial stiffness in CKD remain uncertain. To assess the effects of non-calcium-based phos...